Nanobiotix: Funding, Investors & Team (Sep 2026)
Founded in 2003, Nanobiotix is at the forefront of nanomedicine and is committed to revolutionizing patient outcomes by utilizing nanophysics in cellular treatment. The company's core philosophy centers around creating innovative physical-based approaches to address the pressing medical needs and challenges faced by many. With its cutting-edge technology, NBTXR3, Nanobiotix aims to significantly enhance the benefits of radiotherapy for cancer patients. Additionally, their Immuno-Oncology program holds great potential in advancing cancer immunotherapies. Nanobiotix is publicly traded on Euronext and the Nasdaq Global Select Market and is headquartered in Paris, France, with additional offices in the United States, Spain, and Germany. For more information, visit www.nanobiotix.com.
Nanobiotix has raised $366M across 3 funding rounds on record, the most recent an undisclosed round of $116M announced in May 2026.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Nanobiotix Company Profile and Key Stats
Latest funding round on record: May 2026.
Nanobiotix Funding Rounds
Nanobiotix raised $220M in an undisclosed round announced in May 2021.
2.5 years later, an undisclosed round of $30.1M was announced in Nov 2023.
2.5 years later, an undisclosed round of $116M was announced in May 2026.
Nanobiotix Founders and Leadership Team
Contact details for the Nanobiotix team: 1 of 1 has an email address on file.
Start 14-day free trial →Nanobiotix Funding Compared to Other Biotechnology Startups
Nanobiotix's latest round of $116M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Nanobiotix in Biotechnology and Paris
Companies Similar to Nanobiotix
Brenus Pharma is a platform that uses allogeneic techniques to create immune therapy with the goal of…
TISSIUM is a privately owned medical device company based in Paris, France that is dedicated to the rapid…
NicOx is a biopharmaceutical company that focuses on creating and selling nitric oxide-donating drugs for…
Advicenne is a specialty pharmaceutical company dedicated to improving the lives of patients who suffer from…
One Biosciences was founded in Paris, Ile-de-France, France by Magali Richard, David Schilansky, and Céline…
Inventiva Pharma is a biopharmaceutical company in the clinical stage that focuses on creating oral small…
NETRIS Pharma develops therapeutic molecules for treating cancer by targeting dependence receptors for the…
AbIONYX Pharma is a biotechnology company that is focused on providing innovative therapies for indications…
Theraclion specializes in high-tech medical equipment using high-intensity focused ultrasound (HIFU). They…
Abivax, a clinical stage biotechnology company, is mobilizing the body’s natural immune machinery to treat…
AB Science was established in 2001 by a group of individuals in the medical and business fields who are…
Kahimmune Therapeutics is a cutting-edge biotech startup that is repurposing the cancer immunopeptidome to…
Nanobiotix Funding FAQs
What does Nanobiotix do?
Founded in 2003, Nanobiotix is at the forefront of nanomedicine and is committed to revolutionizing patient outcomes by utilizing nanophysics in cellular treatment. The company's core philosophy centers around creating innovative physical-based approaches to address the pressing medical needs and challenges faced by many. With its cutting-edge technology, NBTXR3, Nanobiotix aims to significantly enhance the benefits of radiotherapy for cancer patients. Additionally, their Immuno-Oncology program holds great potential in advancing cancer immunotherapies. Nanobiotix is publicly traded on Euronext and the Nasdaq Global Select Market and is headquartered in Paris, France, with additional offices in the United States, Spain, and Germany. For more information, visit www.nanobiotix.com.
How much funding has Nanobiotix raised?
Nanobiotix has raised $366M across 3 rounds on record. The most recent is an undisclosed round of $116M announced in May 2026.
When did Nanobiotix last raise funding?
Nanobiotix's most recent funding round on record is an undisclosed round of $116M, announced in May 2026.
Who is the CEO of Nanobiotix?
Laurent Levy is listed as CEO at Nanobiotix.
Where is Nanobiotix headquartered?
Nanobiotix is based in Paris, Ile-De-France, France.
How many employees does Nanobiotix have?
Nanobiotix is in the 101-250 employee band.
How does Nanobiotix's funding compare to other Biotechnology startups?
Nanobiotix's latest round of $116M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Nanobiotix Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Nanobiotix is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.